MoonLake Immunotherapeutics Announces Successful Outcome on both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis

14·06·2024

Nanobodies: a promising tool to perturb ApoE4 activity in Alzheimer's disease pathology

04·06·2024

VUB Team Develops Nanobody-Based Technology Against Liver Inflammation

29·02·2024

Laboratory Animals - General Code of Animal Welfare in China

29·02·2024

Interpretation of Molecular Sieve Results

29·02·2024

Journey in Light & Shadows of Nanobodies - the Application of Nanobodies in Medical Imaging

29·02·2024